Radiotherapy – Medxy AI

$Advancing Radiotherapy in High-Grade Glioma: Targeted Volume Reduction with Hypofractionated Simultaneous Boost IMRT$

Advancing Radiotherapy in High-Grade Glioma: Targeted Volume Reduction with Hypofractionated Simultaneous Boost IMRT

By MedXY 08/23/2025

A randomized trial demonstrates that modified target delineation integrating multimodal MRI and white matter tractography with moderately hypofractionated radiotherapy achieves comparable survival outcomes to standard IMRT while reducing irradiation volumes in high-grade glioma patients.

Clinical Updates Wellness & Lifestyle

Reduced Elective Radiotherapy Dose in Head and Neck Cancer: New Evidence from the UPGRADE-RT Trial

By MedXY 08/07/2025

The UPGRADE-RT multicenter trial confirms that lowering elective neck irradiation dose in definitive radiotherapy for head and neck cancer maintains disease control and improves quality of life, reducing toxicity without increasing recurrence risk.

$Early Toxicity Comparison of Moderately Hypofractionated Radiotherapy and Stereotactic Body Radiotherapy in Prostate Cancer: Insights from the PACE-C Trial$

Clinical Updates Wellness & Lifestyle

Early Toxicity Comparison of Moderately Hypofractionated Radiotherapy and Stereotactic Body Radiotherapy in Prostate Cancer: Insights from the PACE-C Trial

By MedXY 08/03/2025

The PACE-C phase 3 trial shows that stereotactic body radiotherapy (SBRT) and moderately hypofractionated radiotherapy (MHRT) have comparable early toxicity profiles in intermediate- and high-risk prostate cancer patients.